Effect of Azithromycin in Preventing Premature Labour

Sponsor
Beni-Suef University (Other)
Overall Status
Completed
CT.gov ID
NCT05465304
Collaborator
(none)
200
1
6.9
28.9

Study Details

Study Description

Brief Summary

This is a prospective observational case controlled study. The control group will include pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy.

The test group will involve pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin

Condition or Disease Intervention/Treatment Phase

Detailed Description

A prospective randomized clinical study was conducted in the outpatient clinic of the gynecology department of Beni Suef University Hospital, Beni-Suef, Egypt, between October 01, 2021, and April 30, 2022. The study included 211 pregnant women aged between 20 to 41 years. These patients were randomized into three groups.

The first group which was the control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy. While the second group which was the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month.

. The third group was the second test group in which the pregnant women administerated Azithromycin and clindamycin (Dalacin®) vaginal gel 5 times per month.

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Effect of Azithromycin on Pregnancy Prolongation in Women at Risk for Premature Labour
Actual Study Start Date :
Oct 1, 2021
Actual Primary Completion Date :
Apr 1, 2022
Actual Study Completion Date :
Apr 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Control group

control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy.

Azithromycin group

the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month

Drug: Azithromycin
The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated

Azithromycin plus Clindamycin group

the second test group in which the pregnant women administerated Azithromycin and clindamycin (Dalacin®) vaginal gel 5 times per month.

Drug: Azithromycin
The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated

Outcome Measures

Primary Outcome Measures

  1. Effect of Azithromycin in preventing premature labour [6 monthes]

    Main outcome was the number of days between diagnosis and composite event, defined as delivery or rupture of membranes or 2nd intervention aimed at prolonging pregnancy (such as cerclage or tocolysis) or censure (maternal death or transfer). The three groups were compared regarding this number of days

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Pregnant women with <34 weeks of gestation,

  • Hospitalization for risk of preterm labour,

  • Threat of preterm labour, or preterm labour itself.

  • Threat of preterm labour and preterm labour will have to be diagnosis cited in the medical record by the physician.

  • Women at risk of preterm labour must have one of the following conditions cited in their record: sludge, short cervix, cerclage, or bulging membranes

Exclusion Criteria:
  • Patients were excluded from the current study in case of the use of antibiotics within 14 days before the admission (except for pericerclage prophylaxis, or streptococcus B prophylaxis), PPROM or fetal extraction required <37 weeks.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beni-Suef University teaching Hospital Banī Suwayf Beni-Suef Egypt 62511

Sponsors and Collaborators

  • Beni-Suef University

Investigators

  • Principal Investigator: Raghda R.S Hussein, Beni-Suef University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Raghda R.S. Hussein, Assistant Professor of Clinical Pharmacy, Beni-Suef University
ClinicalTrials.gov Identifier:
NCT05465304
Other Study ID Numbers:
  • REC-H-PhBSU-21022
First Posted:
Jul 19, 2022
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022